45 studies found for: " December 29, 2010":" January 28, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine
Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV
Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
Ethnicity Data in HIV Positive Men Who Have Sex With Men
TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients
Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Lenalidomide in Kaposi Disease Associated With HIV Infection
Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients
A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
Study on Immunopathogenesis in HIV and Hepatitis C Coinfection
The Pharmacology/Aging Clinic
Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
Recovery Management Intervention in China
† Indicates status has not been verified in more than two years